Vandetanib (Caprelsa®)

Assessment Status Rapid review complete
Drug Vandetanib
Brand Caprelsa®
Indication For the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Assessment Process
Rapid review commissioned 06/06/2013
Rapid review completed 03/07/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.